Interestingly, only a fraction (~25%) of these cancers manifested the EFNA1-SE signature, with detection rates ranging from 5% to 39%, notably lower than the 56% prevalence observed in CC samples (Supplemental Figure 5F). The gene discussed is EFNA1; the disease is cancer.